Key Highlights
- Thalassemia is an inherited blood condition that can influence both maternal health and pregnancy outcomes when left undetected.
- Early carrier screening, ideally before conception, gives couples the clarity they need to plan with confidence.
- If both partners carry a Thalassemia gene, there is a 25% chance in each pregnancy that the baby will inherit a severe form of the condition.
- Preimplantation genetic testing (PGT-M) through IVF can prevent severe Thalassemia from being passed on to children.
- Bangkok Central Clinic offers advanced genetic testing with NGS technology to help carrier couples select healthy embryos before transfer.
Starting a family is one of the most personal journeys a couple can take, and it begins with understanding the health factors that may shape that path. For couples in Southeast Asia and other regions where Thalassemia is common, knowing your carrier status before conceiving can change the course of your pregnancy planning entirely. This guide covers what Thalassemia is, how Thalassemia in pregnancy can affect both mother and baby, and how Bangkok Central Clinic uses advanced genetic testing to support couples at every stage.
What Is Thalassemia?
Thalassemia is a group of inherited blood disorders where the body produces less hemoglobin than normal. Hemoglobin is the protein in red blood cells that carries oxygen to tissues and organs throughout the body. When production falls short, the result is chronic anemia that ranges from barely noticeable to life-threatening.
The condition is passed down from parents to children through genes, which means a person can carry a Thalassemia gene without ever showing symptoms. Roughly 7% of the global population carries some form of Thalassemia, with higher prevalence among people of Southeast Asian, South Asian, Middle Eastern, African, and Mediterranean backgrounds.
Alpha Thalassemia
This form occurs when one or more of the four alpha-globin genes are missing or mutated. The clinical picture depends entirely on how many genes are affected:
- One gene affected (silent carrier): No symptoms, normal blood counts. The carrier status is typically found only through genetic screening.
- Two genes affected (Alpha Thalassemia Trait): May cause mild anemia and slightly smaller red blood cells. Most people with this trait feel healthy and may never know they carry it.
- Three genes affected (Hemoglobin H Disease): Moderate to severe anemia that may require blood transfusions, particularly during illness or pregnancy.
- Four genes affected (Hemoglobin Bart’s Hydrops Fetalis): The most severe form. Without in-utero intervention, this condition is almost always fatal before or shortly after birth.
Beta Thalassemia
Beta Thalassemia results from mutations in the beta-globin gene. Beta Thalassemia Minor (one mutated gene) usually causes only mild anemia. Beta Thalassemia Major, also called Cooley’s anemia, occurs when both beta-globin genes are affected and requires lifelong blood transfusions and ongoing medical care.
How Thalassemia Affects Pregnancy
Couples often ask: does Thalassemia affect pregnancy? The answer depends on the type and severity of the condition, but in many cases, yes, it does.
Effects On Maternal Health
Pregnancy naturally raises the body’s demand for iron and oxygen. For women who carry a Thalassemia gene or have a mild form of the disease, this increased demand can worsen existing anemia. Women with Alpha Thalassemia in pregnancy, particularly those with Hemoglobin H Disease, may experience fatigue that goes well beyond typical pregnancy tiredness. Some may require blood transfusions to maintain safe hemoglobin levels during the second and third trimesters.
Research also shows that women with more significant forms of Thalassemia face a higher risk of gestational diabetes and preeclampsia. Folic acid supplementation is routinely recommended to support red blood cell production, and regular prenatal monitoring with a care team experienced in Thalassemia management is essential for a safe outcome.
Risks To The Baby
When both parents carry a Thalassemia gene, every pregnancy carries a 25% chance that the baby will inherit two copies and develop a severe form of the disease. For Alpha Thalassemia, the most serious possibility is Hemoglobin Bart’s Hydrops Fetalis, which causes severe fetal anemia and heart failure. For Beta Thalassemia, two mutated genes result in Thalassemia Major, a condition requiring lifelong transfusions from infancy.
Carriers themselves are usually healthy and unaware of their status. This is precisely why a Thalassemia screening test in pregnancy planning is so important, especially for couples from high-prevalence populations.
A Positive Outlook
Most carriers experience smooth, healthy pregnancies when their condition is monitored. The key is identifying carrier status early so that the right care plan is in place before conception or in the first trimester.
Why Screening Before Pregnancy Matters
The most effective way to manage Thalassemia risk is to identify carrier status before conception. Preconception carrier screening involves a straightforward blood test, typically a complete blood count (CBC) followed by hemoglobin electrophoresis or DNA analysis if results suggest a possible Thalassemia gene.
The American College of Obstetricians and Gynecologists (ACOG) recommends carrier screening for individuals from high-risk populations, and the CDC supports both newborn and preconception screening as part of reproductive planning. When both partners are screened, the couple gains a clear picture of their genetic risk profile.
A Thalassemia screening test in pregnancy planning gives couples more time and more options. If only one partner is a carrier, the chance of having a child with a severe form is very low. If both partners carry a Thalassemia gene, several paths are available:
- Natural conception with prenatal monitoring: Couples may choose to conceive naturally and undergo prenatal diagnostic testing (CVS or amniocentesis) during pregnancy to check whether the baby is affected.
- IVF with preimplantation genetic testing (PGT-M): Embryos are screened for the specific Thalassemia mutation before transfer, allowing couples to select unaffected embryos and avoid the emotional weight of mid-pregnancy decisions.
- Donor gamete options: In certain cases, using donor eggs or sperm from a non-carrier can eliminate the risk of passing on a severe form.
Types Of Thalassemia Screening Tests In Pregnancy Planning
Several tests can be used depending on whether screening happens before or during pregnancy:
- Complete blood count (CBC): A standard blood test that measures hemoglobin levels, red blood cell size (MCV), and hemoglobin content per cell (MCH). Low values in these markers can suggest Thalassemia Trait and trigger further testing.
- Hemoglobin electrophoresis: This test separates different types of hemoglobin in a blood sample to detect abnormal patterns linked to Beta Thalassemia and certain Alpha Thalassemia variants.
- DNA analysis (genetic testing): The most precise method. It identifies specific mutations in the alpha-globin or beta-globin genes and is particularly useful for confirming Alpha Thalassemia deletions that may not appear on electrophoresis.
- Prenatal diagnostic testing: For couples already pregnant, chorionic villus sampling (CVS) at 10 to 13 weeks or amniocentesis after 16 weeks can determine whether the fetus has inherited a severe form. These tests carry a small procedural risk and are typically offered when both parents are confirmed carriers.
- Preimplantation genetic testing for monogenic disorders (PGT-M): During IVF, embryos are biopsied at the blastocyst stage and tested for specific Thalassemia mutations. Only unaffected embryos are selected for transfer, giving couples the ability to prevent the condition before pregnancy begins. This approach is a key part of Thalassemia in pregnancy treatment planning for carrier couples.
How NGS And Advanced Genetic Testing Help Couples Plan
For carrier couples who choose IVF, preimplantation genetic testing for monogenic disorders (PGT-M) is the most proactive approach to Thalassemia in pregnancy treatment. Through IVF, embryos are developed to the blastocyst stage (day 5 or 6), and a small number of cells are biopsied from the outer layer for genetic analysis. Only embryos confirmed to be unaffected are recommended for transfer.
What Is NGS And How Does It Work?
Next-Generation Sequencing (NGS) is the technology that has made this process faster and more reliable. Unlike older methods that could analyze only a limited number of chromosomes, NGS reads all 24 types of chromosomes simultaneously, producing over one million data points per embryo. This level of detail allows the lab to detect not only specific gene mutations but also subtle chromosomal deletions and duplications that earlier techniques would miss.
Published clinical data shows that NGS-based PGT for Thalassemia achieves conclusive results in 100% of biopsied embryos, with clinical pregnancy rates of approximately 60% per frozen embryo transfer cycle and prenatal diagnosis results fully consistent with the NGS findings.
Combining PGT-M With PGT-A
When PGT-M (monogenic disease testing) is combined with PGT-A (aneuploidy screening), couples gain two layers of embryo selection. The first layer identifies embryos free of Thalassemia. The second checks that those embryos have the correct number of chromosomes, reducing the risk of miscarriage and failed implantation. Both tests are performed from the same biopsy, so there is no additional risk to the embryo.
NGS testing in Bangkok at Bangkok Central Clinic provides this dual-screening capability, offering carrier couples a clear, evidence-based path toward healthy children.
Bangkok Central Clinic’s Approach To Family Planning
Bangkok Central Clinic offers a comprehensive suite of fertility and genetic testing services built around couples navigating Thalassemia carrier status. The clinic’s approach covers every stage of the process:
- Carrier screening and genetic counseling: Both partners receive thorough blood work and genetic analysis. A dedicated team explains results in detail so couples understand their specific risk and their available options before making any treatment decision.
- IVF with PGT-M for Thalassemia: For carrier couples, the IVF program includes embryo biopsy at the blastocyst stage with genetic analysis performed using NGS technology. Only embryos that are unaffected or are carriers (without having the disease) are recommended for transfer.
- Combined PGT-M and PGT-A screening: Couples can opt for simultaneous monogenic disease testing and chromosomal screening from a single biopsy. This maximizes the information available for embryo selection without adding procedural risk.
- Personalized support for local and international patients: The clinic’s team of fertility specialists, embryologists, and patient coordinators provides end-to-end guidance with transparent pricing and clear communication at every consultation.
If you or your partner have a family history of Thalassemia, or if you come from a region where the condition is prevalent, a conversation with a fertility specialist is a practical first step. Contact Bangkok Central Clinic to schedule a consultation and learn how advanced genetic testing can support your family planning goals.
References:
- Pregnancy and Thalassemia. Retrieved August 10, 2026, from
https://www.nhlbi.nih.gov/health/thalassemia/pregnancy - Carrier Screening for Hemoglobinopathies: Sickle Cell Disease and Thalassemia. Retrieved August 10, 2026, from
https://www.acog.org/womens-health/faqs/carrier-screening-for-hemoglobinopathies - Using Affected Embryos to Establish Linkage Phase in Preimplantation Genetic Testing for Thalassemia. Retrieved August 10, 2026, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055750/ - Thalassemia: Diagnosis and Treatment. Retrieved August 10, 2026, from
https://www.mayoclinic.org/diseases-conditions/thalassemia/diagnosis-treatment/drc-20355001 - Fertility and Pregnancy in Alpha-Thalassaemia: Guidelines for the Management of Alpha-Thalassaemia. Retrieved August 10, 2026, from
https://www.ncbi.nlm.nih.gov/books/NBK602220/ - Thalassemia. Retrieved August 10, 2026, from
https://www.marchofdimes.org/find-support/topics/planning-baby/thalassemia
Frequently Asked Questions About Thalassemia And Pregnancy (FAQs)
Q: Does Thalassemia Affect Pregnancy Outcomes?
A: Yes, Thalassemia in pregnancy can increase the risk of anemia, fatigue, and, in more significant cases, complications such as preeclampsia or the need for blood transfusions. Carriers with mild forms typically have healthy pregnancies with proper monitoring. The greatest concern arises when both parents carry a Thalassemia gene, as there is a 25% chance in each pregnancy that the baby will inherit a severe form of the disease.
Q: When Should Couples Get A Thalassemia Screening Test Before Pregnancy?
A: Both partners should ideally be screened before conception. A complete blood count and hemoglobin electrophoresis can identify carrier status, and DNA analysis may be recommended for Alpha Thalassemia confirmation. Screening before pregnancy provides the most time to evaluate options, including IVF with preimplantation genetic testing if both partners are carriers.
Q: What Is The Recommended Thalassemia In Pregnancy Treatment For Carriers?
A: For carriers with mild anemia, Thalassemia in pregnancy treatment typically includes folic acid supplementation, regular hemoglobin monitoring, and nutritional support throughout each trimester. Women with Hemoglobin H Disease or other more significant forms may need blood transfusions during pregnancy. Working with a medical team experienced in Thalassemia care is the single most important step.
Q: Can Thalassemia Be Prevented In Future Children?
A: While Thalassemia cannot be cured, it can be prevented from being passed on through advanced genetic testing. Preimplantation genetic testing for monogenic disorders (PGT-M) during IVF identifies embryos that are unaffected by Thalassemia before transfer. NGS testing in Bangkok at Bangkok Central Clinic provides this screening with high accuracy, helping carrier couples have healthy children without passing on the condition.
Q: How Does Alpha Thalassemia In Pregnancy Differ From Beta Thalassemia?
A: Alpha Thalassemia in pregnancy involves missing or mutated alpha-globin genes and ranges from a silent carrier state (one gene) to the fatal Hemoglobin Bart’s Hydrops Fetalis (four genes). Beta Thalassemia involves mutations in the beta-globin gene and ranges from mild trait to transfusion-dependent Thalassemia Major. Both types are detectable through carrier screening and can be managed with appropriate prenatal care, genetic counseling, and, when needed, preimplantation genetic testing.
